Request Demo
Recent blog posts
Latest Hotspot
8 min read
Aprocitentan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Aprocitentan is a Small molecule drug targeting ETA x ETB, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Efinopegdutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Efinopegdutide is a Fusion protein targeting GCGR x GLP-1R, at Phase 2. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO.
Latest Hotspot
8 min read
Pelacarsen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Pelacarsen is a ASO targeting Lp(a), at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Baxdrostat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Baxdrostat is a Small molecule drug targeting CYP11B2, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Mazdutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Mazdutide is a Synthetic peptide targeting GCGR x GLP-1R, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Obexelimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Obexelimab is a Bispecific antibody targeting CD19 x CD32B, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Aficamten Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Aficamten is a Small molecule drug targeting Cardiac myosin, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Sacituzumab tirumotecan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Sacituzumab tirumotecan is a Antibody drug conjugate (ADC) targeting Top I x Trop-2, at Approved. This 2026 report reviews clinical evidence, IP, deals.
Latest Hotspot
8 min read
Brensocatib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Brensocatib is a Small molecule drug targeting DPP-1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Resmetirom Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Resmetirom is a Small molecule drug targeting THR-β, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Elafibranor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Elafibranor is a Small molecule drug targeting PPARα x PPARδ, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Seladelpar Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Seladelpar is a Small molecule drug targeting PPARδ, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.